Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Abstract Text:

George V Papatheodoridis,Spilios Manolakopoulos,Geoffrey Dusheiko,Athanasios J Archimandritis,George V Papatheodoridis,Spilios Manolakopoulos,Geoffrey Dusheiko,Athanasios J Archimandritis,

Currently available options for the treatment of chronic hepatitis B virus (HBV) infection include standard and pegylated interferon alfa and four oral antiviral agents (lamivudine, adefovir, entecavir, and telbivudine). These treatment strategies are either therapies of finite duration that aim to achieve sustained off-therapy responses, or long-term treatments that aim to maintain on-therapy remission. Pegylated interferon alfa may offer higher sustained off-therapy responses after 1 year, but most patients do not respond. Oral antivirals are the only candidates for long-term treatment of patients with chronic HBV infection. Viral suppression has favourable effects on patients' outcome and modifies the natural history of the disease. Viral resistance is the main drawback of long-term antiviral therapy. Lamivudine monotherapy is associated with higher resistance (year 1, 10-27%; year 2, 37-48%; year 4, 60-65%) than adefovir (year 1, 0%; year 2, 3%; year 5, 29%) or telbivudine (year 1, 3-4%; year 2, 9-22%). Entecavir resistance is rare in naive individuals (year 4, <1%), but increases over time in lamivudine-resistant patients (year 4, 43%). The best strategy for long-term therapy in chronic HBV infection has yet to be established.

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Publishing Authors By Initials

GV Papatheodoridis,S Manolakopoulos,G Dusheiko,AJ Archimandritis,GV Papatheodoridis,S Manolakopoulos,G Dusheiko,AJ Archimandritis,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Lancet infectious diseases

VOLUME: 8

Page Numbers: 167-78

Journal Abbreviation:

ISSN: 1473-3099

DAY: 28

MONTH: 11

YEAR: 2007

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101130150

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

AFFILIATION: 2nd Department of Internal Medicine, Athens University School of Medicine, Hippokration General Hospital of Athens, Athens, Greece.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Lancet Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection Related Publications

• A 70-year-old stock-breeder with tricuspid valve and defibrillator lead brucella endocarditis.
• Adipokines and insulin resistance in chronic hepatitis C.
• Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation.
• An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features.
• Angioimmunoblastic T-cell lymphoma-associated arthritis: case report and literature review.
• Campylobacter fetus bacteraemia in a healthy individual: clinical and therapeutical implications.
• Changes of liver and muscle enzymes activity in patients with rigor.
• Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes.
• Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C.
• Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
• Myelodysplastic syndrome presenting as acquired ichthyosis.
• Performance Characteristics of Microparticle Enzyme and Chemiluminescence Immunoassays for Measurement of Anti-HBc Immunoglobulin M in Sera of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection.
• Pseudohyperkalemia in serum: a new insight into an old phenomenon.
• Sensorineural hearing loss complicating severe rickettsial diseases: report of two cases.
• Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity.
• Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
• Severe rhabdomyolysis with hypoglycemia in an adult patient with carnitine palmitoyltransferase II deficiency.
• Systemic Vasculitis With Gastrointestinal Involvement in an HIV-Infected Adult.
• Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.
• Usefulness of enzyme-linked immunosorbent assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Addendum.
• Usefulness of enzyme-linked immunospot assay (elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.